Fosravuconazole + benznidazole for chagas disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 30 Nov 2016: Trial started, NCT03378661
  2. 20 Dec 2017: Trial registered, NCT03378661

The trials

NCT03378661: BENDITA BEnznidazole New Doses Improved Treatment and Associations

State
State not given
Phase
Phase 2
People
210 taking part
Started
30 Nov 2016
Primary completion
28 Jan 2018
Arms
BZN 150 mg - 4 wks / E1224 300 mg, BZN 300 mg (weekly) 8 wks / E1224 300 mg
Results
None posted
  1. 30 Nov 2016: Trial started
  2. 20 Dec 2017: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.